Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/17/2025

Management of Pain and Bleeding Associated with Intrauterine Device (IUD) Insertion

Introduction to IUD Management

  • The American College of Obstetricians and Gynecologists recommends that nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxeno for 5-7 days are the first line of treatment for pain after IUD insertion 1
  • The Centers for Disease Control and Prevention (CDC) suggests that NSAIDs can reduce menstrual blood loss by 26-60% during the days of bleeding 1

Pharmacological Interventions

  • NSAIDs such as ibuprofen, naproxeno, ácido mefenámico, ácido flufenámico, and diclofenaco sódico are recommended for short-term treatment (5-7 days) during the days of bleeding 2
  • The American Academy of Pediatrics recommends that IUDs are appropriate for adolescents, with failure rates less than 1% 4
  • The use of aspirin is not recommended for heavy menstrual bleeding, as it has not shown benefits and may increase blood loss 2

Evaluation and Treatment

  • Before initiating treatment for pain or bleeding, it is essential to rule out underlying gynecological problems such as displaced IUD, sexually transmitted infections, pregnancy, and new uterine pathologies (polyps or fibroids) 1
  • The CDC recommends evaluating persistent bleeding, as it requires additional evaluation and consideration of alternative methods if it persists despite treatment 1

Special Considerations

  • Women with copper IUDs commonly experience increased menstrual bleeding, while those with hormonal IUDs (LNG) typically experience irregular bleeding, but heavy bleeding is uncommon and requires evaluation 2
  • Adolescents require special consideration for confidentiality and ease of use needs 2
  • The American College of Obstetricians and Gynecologists recommends that severe pain after IUD insertion is unusual and should prompt an evaluation to detect unrecognized complications 3